DE69714448T2 - Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymeren - Google Patents
Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymerenInfo
- Publication number
- DE69714448T2 DE69714448T2 DE69714448T DE69714448T DE69714448T2 DE 69714448 T2 DE69714448 T2 DE 69714448T2 DE 69714448 T DE69714448 T DE 69714448T DE 69714448 T DE69714448 T DE 69714448T DE 69714448 T2 DE69714448 T2 DE 69714448T2
- Authority
- DE
- Germany
- Prior art keywords
- drug
- polymer
- solvent
- matrix
- polymer solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 214
- 238000004519 manufacturing process Methods 0.000 title abstract description 7
- 238000002360 preparation method Methods 0.000 title description 25
- 239000013543 active substance Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 claims abstract description 251
- 239000003814 drug Substances 0.000 claims abstract description 251
- 239000011159 matrix material Substances 0.000 claims abstract description 133
- 239000000203 mixture Substances 0.000 claims abstract description 90
- 239000002904 solvent Substances 0.000 claims abstract description 56
- 239000007787 solid Substances 0.000 claims abstract description 30
- 239000003960 organic solvent Substances 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims description 79
- 102000003951 Erythropoietin Human genes 0.000 claims description 50
- 108090000394 Erythropoietin Proteins 0.000 claims description 50
- 229940105423 erythropoietin Drugs 0.000 claims description 50
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 50
- 239000011859 microparticle Substances 0.000 claims description 46
- -1 poly(lactic acid) Polymers 0.000 claims description 32
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 25
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 24
- 230000008569 process Effects 0.000 claims description 23
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 21
- 102000004169 proteins and genes Human genes 0.000 claims description 21
- 108090000623 proteins and genes Proteins 0.000 claims description 21
- 230000008014 freezing Effects 0.000 claims description 19
- 238000007710 freezing Methods 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical group ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 238000013467 fragmentation Methods 0.000 claims description 12
- 238000006062 fragmentation reaction Methods 0.000 claims description 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 239000007789 gas Substances 0.000 claims description 8
- 230000009477 glass transition Effects 0.000 claims description 8
- 238000000227 grinding Methods 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 229920001577 copolymer Polymers 0.000 claims description 7
- 229910052751 metal Inorganic materials 0.000 claims description 7
- 239000002184 metal Substances 0.000 claims description 7
- 239000003607 modifier Substances 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
- QWTDNUCVQCZILF-UHFFFAOYSA-N isopentane Chemical compound CCC(C)C QWTDNUCVQCZILF-UHFFFAOYSA-N 0.000 claims description 6
- 108091033319 polynucleotide Proteins 0.000 claims description 6
- 102000040430 polynucleotide Human genes 0.000 claims description 6
- 239000002157 polynucleotide Substances 0.000 claims description 6
- 229920001184 polypeptide Polymers 0.000 claims description 5
- 230000000069 prophylactic effect Effects 0.000 claims description 5
- 238000005507 spraying Methods 0.000 claims description 5
- 239000004094 surface-active agent Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 4
- 229920013641 bioerodible polymer Polymers 0.000 claims description 4
- 238000003801 milling Methods 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 3
- 108090000790 Enzymes Proteins 0.000 claims description 3
- 108090001061 Insulin Proteins 0.000 claims description 3
- 102000004877 Insulin Human genes 0.000 claims description 3
- 229920001710 Polyorthoester Polymers 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims description 3
- 239000000427 antigen Substances 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- AFABGHUZZDYHJO-UHFFFAOYSA-N dimethyl butane Natural products CCCC(C)C AFABGHUZZDYHJO-UHFFFAOYSA-N 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 229940125396 insulin Drugs 0.000 claims description 3
- 239000004570 mortar (masonry) Substances 0.000 claims description 3
- 229920002635 polyurethane Polymers 0.000 claims description 3
- 239000004814 polyurethane Substances 0.000 claims description 3
- 238000010298 pulverizing process Methods 0.000 claims description 3
- 235000000346 sugar Nutrition 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 101710163270 Nuclease Proteins 0.000 claims description 2
- 239000004952 Polyamide Substances 0.000 claims description 2
- 229920002732 Polyanhydride Polymers 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 239000002585 base Substances 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 2
- 229920002647 polyamide Polymers 0.000 claims description 2
- 229920001610 polycaprolactone Polymers 0.000 claims description 2
- 229920000515 polycarbonate Polymers 0.000 claims description 2
- 239000004417 polycarbonate Substances 0.000 claims description 2
- 229920002721 polycyanoacrylate Polymers 0.000 claims description 2
- 229920002959 polymer blend Polymers 0.000 claims description 2
- 229920006324 polyoxymethylene Polymers 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims 2
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 229910052786 argon Inorganic materials 0.000 claims 1
- 229910001873 dinitrogen Inorganic materials 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000011877 solvent mixture Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 description 56
- 239000002245 particle Substances 0.000 description 47
- 238000009472 formulation Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 239000007943 implant Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 10
- 229920000249 biocompatible polymer Polymers 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 235000012431 wafers Nutrition 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000004005 microsphere Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 239000000725 suspension Substances 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 5
- 238000007906 compression Methods 0.000 description 5
- 230000006835 compression Effects 0.000 description 5
- 239000003094 microcapsule Substances 0.000 description 5
- 238000013268 sustained release Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 4
- 235000011130 ammonium sulphate Nutrition 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 238000013267 controlled drug release Methods 0.000 description 4
- 238000013270 controlled release Methods 0.000 description 4
- 229940088679 drug related substance Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000001125 extrusion Methods 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 3
- 229960003086 naltrexone Drugs 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229960001265 ciclosporin Drugs 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 229940039227 diagnostic agent Drugs 0.000 description 2
- 239000000032 diagnostic agent Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000004952 protein activity Effects 0.000 description 2
- 239000012925 reference material Substances 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 229910001220 stainless steel Inorganic materials 0.000 description 2
- 239000010935 stainless steel Substances 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 101800000414 Corticotropin Proteins 0.000 description 1
- 241001427367 Gardena Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 description 1
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000013967 Monokines Human genes 0.000 description 1
- 108010050619 Monokines Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000005157 Somatostatin Human genes 0.000 description 1
- 108010056088 Somatostatin Proteins 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005266 casting Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229960000258 corticotropin Drugs 0.000 description 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001952 enzyme assay Methods 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 102000044890 human EPO Human genes 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000003887 narcotic antagonist Substances 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920002006 poly(N-vinylimidazole) polymer Polymers 0.000 description 1
- 229920000117 poly(dioxanone) Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229940065514 poly(lactide) Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 239000004632 polycaprolactone Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000012667 polymer degradation Methods 0.000 description 1
- 229920000098 polyolefin Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920002620 polyvinyl fluoride Polymers 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940063122 sandimmune Drugs 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 229960000553 somatostatin Drugs 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003894 surgical glue Substances 0.000 description 1
- 238000013269 sustained drug release Methods 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Polymerisation Methods In General (AREA)
- Processing And Handling Of Plastics And Other Materials For Molding In General (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/649,128 US5817343A (en) | 1996-05-14 | 1996-05-14 | Method for fabricating polymer-based controlled-release devices |
| PCT/US1997/007441 WO1997042940A1 (en) | 1996-05-14 | 1997-05-01 | Method for fabricating polymer-based controlled-release devices |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69714448D1 DE69714448D1 (de) | 2002-09-05 |
| DE69714448T2 true DE69714448T2 (de) | 2002-11-14 |
Family
ID=24603582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69714448T Expired - Fee Related DE69714448T2 (de) | 1996-05-14 | 1997-05-01 | Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymeren |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US5817343A (enExample) |
| EP (1) | EP0914095B1 (enExample) |
| JP (1) | JP2000513333A (enExample) |
| AT (1) | ATE221373T1 (enExample) |
| AU (1) | AU718866B2 (enExample) |
| CA (1) | CA2253667A1 (enExample) |
| DE (1) | DE69714448T2 (enExample) |
| DK (1) | DK0914095T3 (enExample) |
| ES (1) | ES2180982T3 (enExample) |
| PT (1) | PT914095E (enExample) |
| WO (1) | WO1997042940A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303584A1 (de) * | 2003-01-30 | 2004-08-12 | Stauss, Robert, Dr. | Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten |
Families Citing this family (173)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5989463A (en) * | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
| US6013258A (en) * | 1997-10-09 | 2000-01-11 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| US6183746B1 (en) | 1997-10-09 | 2001-02-06 | Zycos Inc. | Immunogenic peptides from the HPV E7 protein |
| AU5532699A (en) * | 1998-09-05 | 2000-03-27 | Seung Jin Lee | Biodegradable particulate polymeric preparation and process for producing thereof |
| KR20000022894A (ko) * | 1998-09-05 | 2000-04-25 | 이승진 | 생분해성 고분자 미립자형 제제 및 그 제조방법 |
| DE19848849A1 (de) * | 1998-10-22 | 2000-04-27 | Knoll Ag | Verfahren zur Herstellung von festen, sphärischen Formen, enthaltend eine biologisch aktive Substanz |
| JP2002534371A (ja) * | 1999-01-06 | 2002-10-15 | コリア リサーチ インスティテュート オブ ケミカル テクノロジー | 水不溶性薬物を含む医薬的活性成分の製造方法及びそれを含む経口投与用医薬組成物 |
| US6159491A (en) * | 1999-02-12 | 2000-12-12 | Biovector Technologies, Inc. | Prolonged release bioadhesive vaginal gel dosage form |
| KR100372751B1 (ko) * | 1999-11-16 | 2003-02-17 | 한국과학기술원 | 생체조직공학용 다공성 생분해성 고분자 지지체의 제조방법 |
| US6440463B1 (en) * | 1999-04-05 | 2002-08-27 | Pharmaceutical Discovery Corporation | Methods for fine powder formation |
| WO2000062759A1 (en) * | 1999-04-16 | 2000-10-26 | Novo Nordisk A/S | Dry, mouldable drug formulation |
| US7759113B2 (en) * | 1999-04-30 | 2010-07-20 | The General Hospital Corporation | Fabrication of tissue lamina using microfabricated two-dimensional molds |
| US7371400B2 (en) | 2001-01-02 | 2008-05-13 | The General Hospital Corporation | Multilayer device for tissue engineering |
| WO2000066036A2 (en) * | 1999-04-30 | 2000-11-09 | Massachusetts General Hospital | Fabrication of vascularized tissue using microfabricated two-dimensional molds |
| US6291013B1 (en) | 1999-05-03 | 2001-09-18 | Southern Biosystems, Inc. | Emulsion-based processes for making microparticles |
| US6444223B1 (en) | 1999-05-28 | 2002-09-03 | Alkermes Controlled Therapeutics, Inc. | Method of producing submicron particles of a labile agent and use thereof |
| IL146814A0 (en) * | 1999-06-04 | 2002-07-25 | Alza Corp | Implantable gel compositions and method of manufacture |
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| EP1074248A1 (en) * | 1999-07-08 | 2001-02-07 | Arnold Hilgers | Delivery system for biological material |
| US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
| US6822086B1 (en) * | 1999-08-09 | 2004-11-23 | The General Hospital Corporation | Drug-carrier complexes and methods of use thereof |
| AU6536400A (en) * | 1999-08-11 | 2001-03-05 | Alkermes Controlled Therapeutics, Inc. | Method of delivering a chemotherapeutic agent to a solid tumor |
| US6284283B1 (en) | 1999-10-21 | 2001-09-04 | Alkermes Controlled Therapeutics, Inc. | Method of producing sub-micron particles of biologically active agents and uses thereof |
| WO2001030320A1 (en) * | 1999-10-22 | 2001-05-03 | Amgen Inc. | Biodegradable microparticles with novel erythropoietin stimulating protein |
| AU2599501A (en) * | 1999-12-29 | 2001-07-09 | Advanced Cardiovascular Systems Inc. | Device and active component for inhibiting formation of thrombus-inflammatory cell matrix |
| US7029700B2 (en) * | 2000-01-14 | 2006-04-18 | Brown University Research Foundation | Micronized freeze-dried particles |
| WO2001052818A1 (en) * | 2000-01-19 | 2001-07-26 | Pharmaceutical Discovery Corporation | Dry powder formulations of antihistamine for nasal administration |
| AU5289001A (en) * | 2000-03-02 | 2001-09-12 | Microchips Inc | Microfabricated devices for the storage and selective exposure of chemicals and devices |
| US7074803B2 (en) * | 2001-03-02 | 2006-07-11 | Durect Corporation | Opioid formulations |
| CA2402790A1 (en) | 2000-04-06 | 2001-10-18 | University Technology Corporation | Compositions and methods for promoting wound healing |
| US7776021B2 (en) | 2000-04-28 | 2010-08-17 | The Charles Stark Draper Laboratory | Micromachined bilayer unit for filtration of small molecules |
| DE60127139T2 (de) * | 2000-07-14 | 2007-12-13 | Novo Nordisk A/S | Verfahren zum formen einer pharmazeutischen zusammensetzung in einem verpackungsmaterial |
| US6362308B1 (en) | 2000-08-10 | 2002-03-26 | Alkermes Controlled Therapeutics Inc. Ii | Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content |
| CA2419115C (en) | 2000-08-15 | 2011-03-08 | Board Of Trustees Of The University Of Illinois | Microparticles, and method and apparatus for forming same |
| US6565888B1 (en) | 2000-08-23 | 2003-05-20 | Alkermes Controlled Therapeutics, Inc. | Methods and compositions for the targeted delivery of biologically active agents |
| ATE506942T1 (de) * | 2000-09-01 | 2011-05-15 | Palmaya Pty Ltd | Pharmazeutische zubereitung und methode diese zu verabreichen |
| US7666445B2 (en) | 2000-10-20 | 2010-02-23 | The Trustees Of The University Of Pennsylvania | Polymer-based surgically implantable haloperidol delivery systems and methods for their production and use |
| AU3941002A (en) | 2000-10-31 | 2002-06-03 | Zycos Inc | Cyp1b1 nucleic acids and methods of use |
| WO2002062352A2 (en) * | 2001-02-07 | 2002-08-15 | Durect Corporation | Devices and methods for management of bone density |
| BR0209914A (pt) * | 2001-05-23 | 2004-04-06 | Hexal Ag | Produto homogeneizado para implantes e micropartìculas |
| US6730772B2 (en) | 2001-06-22 | 2004-05-04 | Venkatram P. Shastri | Degradable polymers from derivatized ring-opened epoxides |
| WO2003014224A1 (en) * | 2001-08-03 | 2003-02-20 | Toray Industries, Inc. | Resin composition and molded article, film, and fiber each comprising the same |
| US7687053B2 (en) | 2001-08-20 | 2010-03-30 | Boston Scientific Scimed, Inc. | Embolic compositions with non-cyanoacrylate rheology modifying agents |
| US8454997B2 (en) | 2001-12-18 | 2013-06-04 | Novo Nordisk A/S | Solid dose micro implant |
| US7190781B2 (en) * | 2002-01-04 | 2007-03-13 | Telefonaktiebolaget Lm Ericsson (Publ) | Message transfer part point code mapping method and node |
| AU2003209227A1 (en) * | 2002-01-14 | 2003-07-30 | The General Hospital Corporation | Biodegradable polyketal polymers and methods for their formation and use |
| CA2476452A1 (en) * | 2002-02-15 | 2003-08-28 | Zycos Inc. | Electroporation methods for introducing bioactive agents into cells |
| US8728510B1 (en) | 2002-03-15 | 2014-05-20 | Advanced Cardiovascular Systems, Inc. | Biocompatible carrier containing a bioadhesive material |
| AU2003220125B2 (en) | 2002-03-20 | 2006-06-15 | Mannkind Corporation | Inhalation apparatus |
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| EP1534269B1 (en) | 2002-07-19 | 2013-10-30 | The General Hospital Corporation | Oxime conjugates and methods for their formation and use |
| GB2399084B (en) * | 2002-07-30 | 2007-01-31 | Univ Liverpool | Porous beads and method of production thereof |
| GB0222522D0 (en) | 2002-09-27 | 2002-11-06 | Controlled Therapeutics Sct | Water-swellable polymers |
| CN1694689A (zh) * | 2002-09-30 | 2005-11-09 | 阿库斯菲尔公司 | 供吸入的缓释多孔微粒 |
| US6800663B2 (en) * | 2002-10-18 | 2004-10-05 | Alkermes Controlled Therapeutics Inc. Ii, | Crosslinked hydrogel copolymers |
| ATE439039T1 (de) | 2003-01-16 | 2009-08-15 | Gen Hospital Corp | Verwendung von dreidimensionalen, mikrogefertigten, mittels gewebetechnologie hergestellten systemen für pharmakologische anwendungen |
| WO2004064752A2 (en) * | 2003-01-22 | 2004-08-05 | Alkermes Controlled Therapeutics, Inc. | Method of preparing sustained release microparticles |
| US7736391B2 (en) | 2003-02-06 | 2010-06-15 | Tonaba Healthscience Ii, Llc | Cosmetic and reconstructive prostheses with a microencapsulated biologically compatible rupture indicator for sustained release and methods of detecting compromise of a prosthesis |
| US20070122487A1 (en) * | 2003-03-19 | 2007-05-31 | University Of Kentucky Research Foundation | (Poly(acryloyl-hydroxyethyl starch)-plga composition microspheres |
| US7051485B2 (en) * | 2003-04-29 | 2006-05-30 | Greg Burnette | Ceiling panel system |
| US7960166B2 (en) | 2003-05-21 | 2011-06-14 | The General Hospital Corporation | Microfabricated compositions and processes for engineering tissues containing multiple cell types |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE10361596A1 (de) * | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| US7790150B2 (en) * | 2003-09-05 | 2010-09-07 | The General Hospital Corporation | Dual phase drug release system |
| CN1856296A (zh) * | 2003-09-30 | 2006-11-01 | 阿库斯菲尔公司 | 可注射的、口服、或局部用缓释药物制剂 |
| JP2007507527A (ja) * | 2003-09-30 | 2007-03-29 | スフェリックス， インコーポレイテッド | 生物学的に活性なナノ粒子治療用因子 |
| US7309500B2 (en) * | 2003-12-04 | 2007-12-18 | The Board Of Trustees Of The University Of Illinois | Microparticles |
| ES2346226T3 (es) * | 2003-12-30 | 2010-10-13 | Augustinus Bader | Uso de la eritropoyetina para la regeneracion de tejido hepatico. |
| AU2005206143B2 (en) * | 2004-01-12 | 2010-12-16 | The Trustees Of The University Of Pennsylvania | Long-term delivery formulations and methods of use thereof |
| US8221778B2 (en) | 2005-01-12 | 2012-07-17 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US8329203B2 (en) * | 2004-01-12 | 2012-12-11 | The Trustees Of The University Of Pennsylvania | Drug-containing implants and methods of use thereof |
| US20050220887A1 (en) * | 2004-01-20 | 2005-10-06 | Alkermes Controlled Therapeutics, Inc. | Method for milling frozen microparticles |
| US20050188921A1 (en) * | 2004-02-27 | 2005-09-01 | Anthony Malone | Matrix assisted pulsed-laser evaporation technique for coating a medical device and associated system and medical device |
| DK1732921T3 (da) * | 2004-04-08 | 2009-02-23 | Wyeth Corp | Thiomidderivater som progesteronreceptormodulatorer |
| JP5039541B2 (ja) * | 2004-04-27 | 2012-10-03 | ワイス・エルエルシー | プロゲステロン受容体調節剤の精製 |
| WO2005110369A2 (en) * | 2004-04-30 | 2005-11-24 | American Pharmaceutical Partners, Inc. | Sustained-release microspheres and methods of making and using same |
| US8062652B2 (en) * | 2004-06-17 | 2011-11-22 | Endo Pharmaceuticals Solutions Inc. | Compositions and methods for treating precocious puberty |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| EP2594259A1 (en) | 2004-08-04 | 2013-05-22 | Brookwood Pharmaceuticals, Inc. | Methods for manufacturing delivery devices and devices thereof |
| GB0417401D0 (en) | 2004-08-05 | 2004-09-08 | Controlled Therapeutics Sct | Stabilised prostaglandin composition |
| KR101273120B1 (ko) | 2004-08-20 | 2013-06-13 | 맨카인드 코포레이션 | 다이케토피페라진 합성의 촉매 작용 |
| KR20130066695A (ko) | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| US8367099B2 (en) | 2004-09-28 | 2013-02-05 | Atrium Medical Corporation | Perforated fatty acid films |
| US9000040B2 (en) | 2004-09-28 | 2015-04-07 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2006036967A1 (en) * | 2004-09-28 | 2006-04-06 | Atrium Medical Corporation | Solubilizing a drug for use in a coating |
| US9801982B2 (en) | 2004-09-28 | 2017-10-31 | Atrium Medical Corporation | Implantable barrier device |
| US8312836B2 (en) | 2004-09-28 | 2012-11-20 | Atrium Medical Corporation | Method and apparatus for application of a fresh coating on a medical device |
| US9012506B2 (en) | 2004-09-28 | 2015-04-21 | Atrium Medical Corporation | Cross-linked fatty acid-based biomaterials |
| WO2007011385A2 (en) | 2004-09-28 | 2007-01-25 | Atrium Medical Corporation | Heat cured gel and method of making |
| US8124127B2 (en) | 2005-10-15 | 2012-02-28 | Atrium Medical Corporation | Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings |
| US8834901B2 (en) * | 2004-10-14 | 2014-09-16 | Trustees Of Tufts College | Electrochemically degradable polymers |
| US7748343B2 (en) | 2004-11-22 | 2010-07-06 | The Board Of Trustees Of The University Of Illinois | Electrohydrodynamic spraying system |
| US20080213593A1 (en) * | 2005-01-21 | 2008-09-04 | President And Fellows Of Harvard College | Systems And Methods For Forming Fluidic Droplets Encapsulated In Particles Such As Colloidal Particles |
| DE102005005449A1 (de) * | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| NZ561400A (en) * | 2005-03-11 | 2010-02-26 | Endo Pharmaceuticals Solutions | Controlled release formulations of octreotide |
| US7759312B2 (en) * | 2005-03-11 | 2010-07-20 | Endo Pharmaceuticals Solutions Inc. | Delivery of dry formulations of octreotide |
| CN102614131A (zh) | 2005-09-14 | 2012-08-01 | 曼金德公司 | 以提高结晶微粒表面对活性试剂的亲和力为基础的药物配制方法 |
| US9278161B2 (en) | 2005-09-28 | 2016-03-08 | Atrium Medical Corporation | Tissue-separating fatty acid adhesion barrier |
| US9427423B2 (en) * | 2009-03-10 | 2016-08-30 | Atrium Medical Corporation | Fatty-acid based particles |
| US7669732B2 (en) * | 2005-10-25 | 2010-03-02 | Imi Cornelius Inc. | Cup lid dispenser |
| WO2007098500A2 (en) | 2006-02-22 | 2007-08-30 | Mannkind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| US8231907B2 (en) * | 2006-03-21 | 2012-07-31 | Morehouse School Of Medicine | Nanoparticles for delivery of active agents |
| CA2649915A1 (en) * | 2006-04-20 | 2007-11-01 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| US8747870B2 (en) | 2006-04-20 | 2014-06-10 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| GB0613333D0 (en) | 2006-07-05 | 2006-08-16 | Controlled Therapeutics Sct | Hydrophilic polyurethane compositions |
| GB0613638D0 (en) | 2006-07-08 | 2006-08-16 | Controlled Therapeutics Sct | Polyurethane elastomers |
| US20080075777A1 (en) * | 2006-07-31 | 2008-03-27 | Kennedy Michael T | Apparatus and methods for preparing solid particles |
| ITMI20061538A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Impianti sottocutanei in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| ITMI20061545A1 (it) * | 2006-08-02 | 2008-02-03 | Mediolanum Pharmaceuticals Ltd | Particelle in grado di rilasciare il principio attivo per un periodo prolungato di tempo |
| GB0620685D0 (en) | 2006-10-18 | 2006-11-29 | Controlled Therapeutics Sct | Bioresorbable polymers |
| WO2008057344A2 (en) | 2006-11-06 | 2008-05-15 | Atrium Medical Corporation | Coated surgical mesh |
| US9492596B2 (en) | 2006-11-06 | 2016-11-15 | Atrium Medical Corporation | Barrier layer with underlying medical device and one or more reinforcing support structures |
| WO2008112495A1 (en) * | 2007-03-09 | 2008-09-18 | Wyeth | Synthesis and characterization of polymorph form iii of 4-(2,(4,4-dimethyl-2-oxooxazolidin-3-yl)thiazol-4-yl)benzonitrile |
| EP2139533A2 (en) * | 2007-04-27 | 2010-01-06 | Endo Pharmaceuticals Solutions Inc. | Implant device release agents and methods of using same |
| DK2868315T3 (en) | 2007-12-04 | 2017-09-04 | Biogen Chesapeake Llc | IMPROVED FORMULATIONS AND PROCEDURES FOR FREEZING DRYING AND THEREOF, LYOFILATES PREPARED |
| US8728528B2 (en) | 2007-12-20 | 2014-05-20 | Evonik Corporation | Process for preparing microparticles having a low residual solvent volume |
| CN102014877B (zh) | 2008-01-25 | 2017-06-06 | 格吕伦塔尔有限公司 | 药物剂型 |
| PL2273983T3 (pl) * | 2008-05-09 | 2017-01-31 | Grünenthal GmbH | Sposób wytwarzania pośredniego preparatu proszkowego i końcowej stałej postaci dawkowania z zastosowaniem etapu zestalania rozpyłowego |
| WO2009143404A1 (en) * | 2008-05-23 | 2009-11-26 | Wyeth | Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression |
| CN104491962B (zh) | 2008-06-13 | 2018-10-23 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2904623T3 (es) | 2008-06-20 | 2022-04-05 | Mannkind Corp | Aparato interactivo para establecer un perfil en tiempo real de esfuerzos de inhalación |
| BRPI0914336A2 (pt) * | 2008-06-25 | 2017-05-30 | Endo Pharmaceuticals Solutions | implante de octreotida com um agente de liberação |
| US8071537B2 (en) * | 2008-06-25 | 2011-12-06 | Endo Pharmaceuticals Solutions Inc. | Implantable device for the sustained release of a polypeptide |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| CN102281870B (zh) | 2008-12-10 | 2015-03-04 | 安徽中人科技有限责任公司 | 新型控释组合物 |
| US8491880B2 (en) * | 2008-12-10 | 2013-07-23 | Mersana Therapeutics, Inc. | Pharmaceutical formulations of biodegradable biocompatible camptothecin-polymer conjugates |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| CA2749993C (en) * | 2009-01-23 | 2016-12-20 | Surmodics Pharmaceuticals, Inc. | Continuous double emulsion process for making microparticles |
| MX2011009512A (es) | 2009-03-11 | 2011-11-29 | Mannkind Corp | Aparato, sistema y metodo para medir la resistencia de un inhalador. |
| US8734845B2 (en) | 2009-06-12 | 2014-05-27 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
| JP2012533585A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化感受性オピオイドのための不正使用防止剤形 |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| US20110038910A1 (en) | 2009-08-11 | 2011-02-17 | Atrium Medical Corporation | Anti-infective antimicrobial-containing biomaterials |
| US8877746B2 (en) * | 2009-08-25 | 2014-11-04 | Cardioklne, Inc | Compositions for delivery of insoluble agents |
| CA2775077C (en) * | 2009-09-22 | 2018-05-01 | Evonik Degussa Corporation | Implant devices having varying bioactive agent loading configurations |
| US9016147B2 (en) | 2009-11-03 | 2015-04-28 | Mannkind Corporation | Apparatus and method for simulating inhalation efforts |
| WO2011095314A2 (en) * | 2010-02-03 | 2011-08-11 | Grünenthal GmbH | Preparation of a powdery pharmaceutical composition by means of an extruder |
| EP2582421A1 (en) | 2010-06-21 | 2013-04-24 | MannKind Corporation | Dry powder drug delivery system and methods |
| EP2593141B1 (en) | 2010-07-16 | 2018-07-04 | Atrium Medical Corporation | Composition and methods for altering the rate of hydrolysis of cured oil-based materials |
| NZ608865A (en) | 2010-09-02 | 2015-03-27 | Gruenenthal Chemie | Tamper resistant dosage form comprising an anionic polymer |
| CA2808219C (en) | 2010-09-02 | 2019-05-14 | Gruenenthal Gmbh | Tamper resistant dosage form comprising inorganic salt |
| CN103348000B (zh) * | 2011-02-07 | 2017-09-22 | 生命技术公司 | 用于稳定敏感化合物的组合物和方法 |
| US8925726B2 (en) | 2011-04-01 | 2015-01-06 | Mannkind Corporation | Blister package for pharmaceutical cartridges |
| WO2012172449A1 (en) | 2011-06-13 | 2012-12-20 | Pfizer Inc. | Lactams as beta secretase inhibitors |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| PT2736497T (pt) | 2011-07-29 | 2017-11-30 | Gruenenthal Gmbh | Comprimido resistente a adulteração proporcionando libertação imediata de fármaco |
| MX348491B (es) | 2011-07-29 | 2017-06-15 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion inmediata de fármaco. |
| JP2014521743A (ja) * | 2011-08-15 | 2014-08-28 | モアハウス スクール オブ メディスン | ガン細胞を特異的に標的とするための送達システムおよびその使用方法 |
| EP2776053A1 (en) | 2011-10-24 | 2014-09-17 | MannKind Corporation | Methods and compositions for treating pain |
| EP2790667B1 (en) | 2011-12-16 | 2017-03-22 | DSM IP Assets B.V. | Process for the manufacturing of a drug delivery system based on a polymer comprising a dispersed bioactive agent |
| BR112014019988A8 (pt) | 2012-02-28 | 2017-07-11 | Gruenenthal Gmbh | Forma de dosagem resistente a socamento compreendendo um composto farmacologicamente ativo e um polímero aniônico |
| ES2692944T3 (es) | 2012-04-18 | 2018-12-05 | Grünenthal GmbH | Forma de dosificación farmacéutica resistente a la manipulación y resistente a la descarga rápida de la dosis |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US9867880B2 (en) | 2012-06-13 | 2018-01-16 | Atrium Medical Corporation | Cured oil-hydrogel biomaterial compositions for controlled drug delivery |
| BR112015000529B1 (pt) | 2012-07-12 | 2022-01-11 | Mannkind Corporation | Inalador de pó seco |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| CA2906817C (en) | 2013-03-15 | 2022-01-18 | Mannkind Corporation | Microcrystalline diketopiperazine compositions and methods |
| JP6445537B2 (ja) | 2013-05-29 | 2018-12-26 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | １個または複数の粒子を含有する改変防止（ｔａｍｐｅｒ−ｒｅｓｉｓｔａｎｔ）剤形 |
| EP3003283A1 (en) | 2013-05-29 | 2016-04-13 | Grünenthal GmbH | Tamper resistant dosage form with bimodal release profile |
| JP6449871B2 (ja) | 2013-07-12 | 2019-01-09 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | エチレン−酢酸ビニルポリマーを含有する改変防止剤形 |
| EP3021834A1 (en) | 2013-07-18 | 2016-05-25 | MannKind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
| CN105517607A (zh) | 2013-08-05 | 2016-04-20 | 曼金德公司 | 吹入设备和方法 |
| WO2015078891A1 (en) | 2013-11-26 | 2015-06-04 | Farmaceutici Formenti S.P.A. | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
| WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2015173195A1 (en) | 2014-05-12 | 2015-11-19 | Grünenthal GmbH | Tamper resistant immediate release capsule formulation comprising tapentadol |
| US9872835B2 (en) | 2014-05-26 | 2018-01-23 | Grünenthal GmbH | Multiparticles safeguarded against ethanolic dose-dumping |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| EP3285745A1 (en) | 2015-04-24 | 2018-02-28 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| US10842750B2 (en) | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| EP3370694A1 (en) | 2015-11-06 | 2018-09-12 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Composition comprising a biocompatible and biodegradable polymer, nanocarries and a drug and methods of making and using the same |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
| IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4818542A (en) * | 1983-11-14 | 1989-04-04 | The University Of Kentucky Research Foundation | Porous microspheres for drug delivery and methods for making same |
| US4703008A (en) * | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
| CH665558A5 (en) | 1985-10-09 | 1988-05-31 | Debiopharm Sa | Phase sepn. prodn. of microcapsules for water soluble pharmaceuticals - using fluoro-substd. aliphatic hydrocarbon as non-solvent in the hardening stage |
| JPS62223112A (ja) | 1986-03-25 | 1987-10-01 | Rooto Seiyaku Kk | 歯周病治療剤 |
| IE59720B1 (en) | 1986-08-11 | 1994-03-23 | Innovata Biomed Ltd | Pharmaceutical formulations comprising microcapsules |
| GB2209937B (en) * | 1987-09-21 | 1991-07-03 | Depiopharm S A | Water insoluble polypeptides |
| AU2902289A (en) | 1987-12-08 | 1989-07-05 | Mark Chasin | Method of forming bioerodible implants for improved controlled drug release |
| FR2634376B1 (fr) * | 1988-07-21 | 1992-04-17 | Farmalyoc | Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation |
| US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
| HU221294B1 (en) * | 1989-07-07 | 2002-09-28 | Novartis Ag | Process for producing retarde compositions containing the active ingredient in a polymeric carrier |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5439688A (en) * | 1989-07-28 | 1995-08-08 | Debio Recherche Pharmaceutique S.A. | Process for preparing a pharmaceutical composition |
| US5478564A (en) * | 1990-02-22 | 1995-12-26 | Teva Pharmaceutical Industries, Ltd. | Preparation of microparticles for controlled release of water-soluble substances |
| JPH05194253A (ja) | 1992-01-16 | 1993-08-03 | Kirin Brewery Co Ltd | 水溶性ポリペプチドホルモンを含む徐放性微小粒子状製剤及びその製造法 |
| DE4201179A1 (de) * | 1992-01-17 | 1993-07-22 | Alfatec Pharma Gmbh | Wirkstoff(e) enthaltendes granulat oder pellet mit einem geruest aus hydrophilen makromolekuelen und verfahren zu seiner herstellung |
| DE69311538D1 (de) * | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
| US5674534A (en) * | 1992-06-11 | 1997-10-07 | Alkermes, Inc. | Composition for sustained release of non-aggregated erythropoietin |
| US5723508A (en) * | 1996-01-25 | 1998-03-03 | Northwestern University | Method of fabricating emulsion freeze-dried scaffold bodies and resulting products |
-
1996
- 1996-05-14 US US08/649,128 patent/US5817343A/en not_active Expired - Lifetime
-
1997
- 1997-01-07 US US08/779,777 patent/US6183781B1/en not_active Expired - Lifetime
- 1997-05-01 DK DK97921491T patent/DK0914095T3/da active
- 1997-05-01 AU AU27517/97A patent/AU718866B2/en not_active Ceased
- 1997-05-01 WO PCT/US1997/007441 patent/WO1997042940A1/en not_active Ceased
- 1997-05-01 ES ES97921491T patent/ES2180982T3/es not_active Expired - Lifetime
- 1997-05-01 AT AT97921491T patent/ATE221373T1/de not_active IP Right Cessation
- 1997-05-01 DE DE69714448T patent/DE69714448T2/de not_active Expired - Fee Related
- 1997-05-01 PT PT97921491T patent/PT914095E/pt unknown
- 1997-05-01 EP EP97921491A patent/EP0914095B1/en not_active Expired - Lifetime
- 1997-05-01 JP JP09540906A patent/JP2000513333A/ja not_active Ceased
- 1997-05-01 CA CA002253667A patent/CA2253667A1/en not_active Abandoned
-
2002
- 2002-03-25 US US10/106,862 patent/US20030031701A1/en not_active Abandoned
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10303584A1 (de) * | 2003-01-30 | 2004-08-12 | Stauss, Robert, Dr. | Verwendung von Erythropoietin (EPO) als ein Beschichtungsmaterial auf medizinischen Implantaten |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2751797A (en) | 1997-12-05 |
| ATE221373T1 (de) | 2002-08-15 |
| DK0914095T3 (da) | 2002-11-11 |
| CA2253667A1 (en) | 1997-11-20 |
| US6183781B1 (en) | 2001-02-06 |
| ES2180982T3 (es) | 2003-02-16 |
| PT914095E (pt) | 2002-11-29 |
| US20030031701A1 (en) | 2003-02-13 |
| US5817343A (en) | 1998-10-06 |
| WO1997042940A1 (en) | 1997-11-20 |
| EP0914095B1 (en) | 2002-07-31 |
| DE69714448D1 (de) | 2002-09-05 |
| EP0914095A1 (en) | 1999-05-12 |
| AU718866B2 (en) | 2000-04-20 |
| JP2000513333A (ja) | 2000-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69714448T2 (de) | Verfahren zur herstellung von präparaten mit kontrollierter wirkstofffreisetzung auf basis von polymeren | |
| DE69814885T2 (de) | Verfahren zur herstellung von arzneiformen mit kontrollierter wirkstoffabgabe auf polymerbasis | |
| DE69332222T2 (de) | Enythropoietin enthaltendes arzneimittelabgabesystem | |
| DE69025334T2 (de) | Herstellungsverfahren für proteinmikrosphären | |
| DE60127822T2 (de) | Komprimierte mikropartikel für trockene injektion | |
| AT407702B (de) | Salze von peptiden mit carboxy-terminierten polyestern | |
| DE69000573T2 (de) | Bei sehr niedriger temperatur zerstaeubte mikrokugeln mit kontrollierter freisetzung. | |
| DE69329295T2 (de) | Wachstumhormon enthaltende mikrosphaeren mit kontrollierter freisetzung | |
| DE69332210T2 (de) | Biologisch abbaubares, schmelzgesponnenes abgabesystem zur kontrollierten freisetzung | |
| DE69711626T2 (de) | Aerodynamische leichtpartikel zur arzneistoffabgabe an die lungen | |
| DE69420632T2 (de) | Verfahren zur Herstellung von Arzneizubereitungen mit verzögerter Wirkstoffabgabe | |
| DE69220317T2 (de) | Mikropartikeln-Zusammenfassung zur verlängerten Freigabe und Herstellung derselbe | |
| DE60027272T2 (de) | Stabile, nichtwässrige, einphasige, biokompatible, viskose Träger und Formulierungen, die diese Träger verwenden | |
| DE69110150T2 (de) | Mikrokapseln mit verzögerter Wirkstoffabgabe. | |
| DE69213739T2 (de) | Osteogene proteine enthaltende arzneimittel | |
| DE69818295T2 (de) | Einhüllungssverfahren | |
| DE69837140T2 (de) | Alginatgele mit verzögerter freisetzung | |
| DE69614685T2 (de) | Mittel zur verzögerten freisetzung von menschlichem wachstumshormon | |
| AT406225B (de) | Formulierungen mit verlangsamter freisetzung wasserlöslicher peptide | |
| DE69706988T2 (de) | Verfahren zur lieferung von zusammensetzungen aus dichten teilchen zur anwendung in transdermale teilchen abgabe | |
| DE69009743T2 (de) | Dosierungsform für dauerverabreichung. | |
| DE69811710T2 (de) | Verfahren zur herstellung von igf-i formulierungen mit verzögerter freisetzung | |
| DE69838750T2 (de) | Zeitverzögerte gelzusammensetzungen mit verlängerter wirkstoffverabreichung | |
| EP1137404A2 (de) | Nanopartikuläre kern-schale systeme sowie deren verwendung in pharmazeutischen und kosmetischen zubereitungen | |
| JPH11513047A (ja) | ヒアルロン酸の微細粒子中に封入された薬物の徐放性組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |